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MYF5 DOES NOT INDUCE APOPTOSIS IN SKELETAL MYOBLASTS BUT IS  
 
REGULATED BY ONCOGENIC RAS EXPRESSION 
 
ALEXANDER P. TALARICO 
 
ABSTRACT 
 
Skeletal myogenesis is initiated by a family of muscle regulatory factors (MRFs) 
composed of the transcription factors MyoD, Myf5, MRF4, and myogenin.  Of 
these, MyoD was the first discovered, is the most studied, and plays a well-
characterized role in skeletal myoblast determination and differentiation. Our 
laboratory has also discovered that MyoD plays an important role in the apoptotic 
process that occurs in a subpopulation of myoblasts induced to differentiate. 
Expression of oncogenic Ras is known to inhibit myoblast differentiation and to 
decrease the expression of MyoD mRNA and protein.  Our laboratory was the 
first to report that expression of oncogenic Ras also blocks the apoptotic process.  
While it is well known that MyoD and Myf5 function somewhat redundantly with 
respect to their role in the differentiation process, neither the role of Myf5 in the 
apoptotic process nor the regulation of Myf5 by oncogenic Ras has been 
investigated.  Herein we report that, unlike MyoD, Myf5 is not sufficient to induce 
apoptosis.  Further, like MyoD, Myf5 expression is decreased in both myoblasts 
and fibroblasts expressing oncogenic Ras.  Additionally, we report that the 
mechanism of this inhibition is not a consequence of reducing Myf5 mRNA 
levels.   
  vi 
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CHAPTER I 
INTRODUCTION 
 
 
1.1 The Skeletal Myoblast Model System 
 
The skeletal muscle system is a useful model for elucidating the cell 
signaling pathways regulating cell differentiation and apoptosis. During 
development, myoblasts are maintained in an actively proliferative state by 
circulating mitogens such as fibroblast growth factor (FGF) (Olson et al. 1985).  
Myoblast migration results in a reduction of the local concentration of such 
mitogens.  Therefore, skeletal myoblasts cultured in vitro can be induced to 
undergo differentiation by mitogen withdrawal (Konigsberg 1971). Specification 
(determination) to the myogenic lineage and eventual differentiation depends on 
a group of basic helix-loop-helix (bHLH) transcription factors known as muscle 
regulatory factors (MRFs).  These factors consist of MyoD, Myf5, MRF4, and 
myogenin (Rudnicki and Jaenisch 1995). In the presence of mitogens, these 
factors are prevented from binding DNA or acting through the interaction with Id 
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and/or histone deacetylases (HDACs) (Olson 1992).  In the absence of mitogens, 
Id is degraded and histone acetyltransferases (HATs) are recruited (Mal et al. 
2001). Differentiation is a stepwise process consisting of cell cycle exit, 
expression of muscle specific genes such as myogenin and myosin heavy chain, 
and fusion of myoblasts into multinucleate myotubes (Andres and Walsh 1996). 
The most frequently used myoblast cell lines are either 23A2 myoblasts (derived 
from 10T½ fibroblasts isolated from C3H mice) or C2C12 myoblasts (also 
isolated from C3H mice).  
 
1.2 Expression And Role Of MRFs During Development 
 
During development, Myf5 expression is typically restricted to the epaxial 
myotome (and transiently in some preneurons) and is signaled for by Sonic 
Hedgehog (Shh) and Wingless-type (Wnt) produced by the notochord and neural 
tube (respectively).  Conversely, MyoD expression is found in the hypaxial 
myotome (Tapscott 2005).  In both cases, MyoD or Myf5 activates expression of 
myogenin during differentiation.  MRF4 expression is known to be induced late in 
the differentiation process.  However, the mechanism controlling MRF4 
expression remains unclear. Myf5 is also capable of inducing MyoD expression, 
and MyoD can positively regulate its own expression and can negatively regulate 
Myf5 expression (Emerson 1993). However, in differentiated myotubes, while 
Myf5 protein levels diminish, MyoD and myogenin continue to be expressed 
while MRF4 is expressed (Chang et al. 2007). 
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Each of the MRFs serves a specific role in development.  Phenotypes of 
gene knockouts of these regulatory factors gives insight as to the importance of 
each MRF.  MyoD knockout mice are phenotypically normal (Emerson 1993).  
Myf5 null mice are delayed in differentiation, display impaired muscle 
regeneration, and show an ongoing slow myopathy, but are otherwise normal 
(Gayraud-Morel et al. 2007).  A knockout of MRF4 has proved problematic as 
different targeting vectors differentially affect the expression of Myf5 due to their 
overlapping enhancers (Chang et al. 2004).  Myogenin knockout mice exhibit a 
lack of skeletal muscle at birth despite the presence of determined myoblasts, 
indicating myogenin’s importance for terminal differentiation but not specification 
(Arnold and Braun 1996).  Complete absence of both determined myoblasts and 
skeletal muscle is observed only in a MyoD/Myf5/MRF4 triple knockout mouse 
indicating that each is capable of specifying the muscle lineage (Ustanina et al. 
2007).  Thus, MRF4 seems to serve a redundant function to MyoD or Myf5 
although during normal development MRF4 is only expressed post-differentiation 
(Gayraud-Morel et al. 2004).  Thus, MyoD and/or Myf5 are considered to be the 
critical regulators of skeletal myoblast specification during development. 
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1.3 Expression And Role Of the MRFs During Regeneration 
 
Satellite cells are adult stem cells which exist at the periphery of mature 
skeletal muscle (Mauro 1961).  Normally quiescent, they are typically activated in 
response to muscle injury, resulting first in proliferation as myoblasts and ending 
in myogenic differentiation and subsequent augmentation of existing muscle 
fibers (Bodine-Fowler 1994; Schultz and McCormick 1994).  These cells express 
MyoD and/or Myf5 when cultured in growth media (GM) (Yablonka-Reuveni et al. 
2008).  Therefore, most established myoblast cell lines such as C2C12 
myoblasts are thus derived from these progenitors.  In GM, 23A2 skeletal 
myoblasts express only MyoD, while C2C12 myoblasts express both MyoD and 
Myf5.  MyoD knockout satellite cells upregulate Myf5, but exhibit a reduced ability 
to differentiate (Rudnicki et al. 1999; Montarras et al. 2000).  Myf5 knockout 
satellite cells also display inhibited differentiation (Gayraud-Morel et al. 2007). 
 
1.4 Coordinated Regulation Of Differentiation And Apoptosis 
 
This laboratory, along with others, has previously reported that mitogen 
withdrawal actually results in two mutually exclusive physiological endpoints; 
70% of cells in a population undergo differentiation while 30% undergo apoptosis 
(Wang and Walsh 1996).  Apoptosis is a crucial component of skeletal 
myogenesis during development and regeneration and is thought to function to 
remove excess myoblasts.  Defective apoptosis can contribute to malignancies 
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such as rhabdomyosarcoma (a cancer of skeletal muscle origin) (Scholl et al. 
2000).  Conversely, excessive apoptosis can worsen degenerative disorders 
such as spinal muscular atrophies, cachexia (muscle wasting), or muscular 
dystrophies and adds to ischemia-reperfusion injury following myocardial 
infarction (Weyman et al. 2002; Miller and Girgenrath 2006). 
 
Cultures of both primary and established myoblast cell lines (23A2, 
C2C12) have been noted to undergo apoptosis when cultured in differentiation 
media (DM) (Shen et al. 2003).  Interestingly, our laboratory has determined that 
10T½ fibroblasts (from which 23A2 myoblasts are derived) quiesce rather than 
undergo either differentiation or apoptosis when cultured in DM (Weyman, 
personal observation).  Since fibroblasts do not express any of the MRFs, one 
possibility was that MyoD was facilitating both differentiation and apoptosis.  
Others have reported that expression of either MyoD or Myf5 is sufficient to 
induce differentiation as monitored by the expression of Myosin Heavy Chain 
(MHC). Our laboratory subsequently determined that ectopic expression of MyoD 
is sufficient to induce apoptosis in 10T½ fibroblasts.  Further, myoblasts silenced 
for MyoD expression are defective for both differentiation and apoptosis.  
However, the ability of Myf5 to induce apoptosis in either myoblasts or fibroblasts 
is, until now, untested. 
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1.5 The Role Of Oncogenic Ras In Skeletal Myoblasts 
 
Cancer is a disease wherein cells proliferate uncontrollably due to 
defective differentiation and/or apoptosis.  The formation of tumors relies on the 
mutation of certain genes (oncogenes and/or tumor suppresor genes) encoding 
the regulatory proteins that ensure that these processes work correctly 
(Spandidos 1986). Approximately 30% of all human malignancies and 50% of 
rhabdomyosarcomas contain a mutant version of the Ras gene (Linardic and 
Counter 2008).  Ras is a GTPase. In response to growth factor signaling, normal 
Ras releases bound GDP and binds GTP.  Ras*GTP initiates several signaling 
cascades.  Ras*GTP is then inactivated via the GTPase activating protein (GAP). 
Oncogenic Ras protein is indifferent to GAP activity and thus remains in the GTP 
bound, constitutively active conformation. Others have shown that the expression 
of oncogenic Ras downregulates the expression of MyoD mRNA and protein and 
inhibits differentiation (Konieczny, et al. 1989). Our laboratory has confirmed that 
23A2 myoblasts expressing an oncogenic constitutively active version of Ras 
(A2:G12V H-Ras) are defective for both differentiation and apoptosis (Weyman 
and Wolfman 1997). 
 
The inhibition of differentiation and apoptosis seen in A2:G12V H-Ras 
myoblasts is likely a consequence of Ras signaling decreasing MyoD expression.  
The mechanism responsible for downregulation of MyoD expression by 
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oncogenic Ras signaling is unknown.  Likewise, the effect of oncogenic Ras 
signaling on Myf5 expression has not been explored until now. 
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CHAPTER II 
MATERIALS AND METHODS 
 
2.1 Cells And Cell Culture 
 
23A2 myoblasts are derived from 10T½ fibroblasts (Pinney et al. 1988). 
The growth of 10T½ fibroblasts and the derivative expressing G12V:H-Ras 
(10T1/2;G12V H-Ras), as well as the growth and differentiation properties of 
23A2 myoblasts and the 23A2 derivative expressing G12V:H-Ras (A2:G12V;H-
Ras myoblasts) have been reported previously.  All cells were cultured on 
gelatin-coated plates and maintained in growth medium (GM), which consists of 
basal modified Eagle’s medium (BME), 10% fetal bovine serum (FBS), and a 1% 
combination of 10,000 I.U./ml penicillin and 10,000 µg/ml streptomycin (1% P/S). 
 Differentiation was induced by switching cells from growth medium to 
differentiation medium (DM), which consists of BME, 1% P/S and 0% FBS.  
Cycloheximide was dissolved in 1ml of ethanol to give a final concentration of 
10mg/ml.  Cells were treated with 1µl/100mm culture dish to inhibit translation. 
 9 
 
2.2 Transient Transfection And B-galactosidase Assay 
 
Equal cell numbers were plated and the next day transfected using 
Lipofectamine Plus per manufacturer’s instructions (Invitrogen).  Following 
overnight culture in GM, cells were washed three times in 1X PBS (phosphate-
buffered saline pH 7.4) and fixed in 2.5% glutaraldehyde solution for five minutes 
at room temperature.  The cells were then incubated with X-Gal solution (.1M 
potassium ferricyanide, .1M potassium ferrocyanide, 1M magnesium chloride, 
40mg/ml X-gal) overnight at 37oC in the absence of carbon dioxide and the 
presence of B-gal activity was detected by counting stained vs. unstained cells.  
 
2.3 Immunoblot Analysis 
 
Samples were rinsed three times in cold 1x phosphate buffered saline 
(PBS) solution and then lysed in p21 lysis buffer (200mM sucrose, 0.1mm EDTA, 
4mM MgCl2, 20mM MOPS pH 7.4, 0.001 percent DNAse, 1 M 
phenylmethylsulfonyl fluoride, and 50 ug/ml each of leupeptin, pepstatin, and 
aprotinin) containing 1% CHAPS. Following protein determination, lysates (100 
µg of total cellular lysate for MHC and MYF5) were denatured in 5x sample buffer 
(10% SDS, 50% glycerol, 10% 2-mercaptoethanol, pH 6.8) and electrophoresed 
through denaturing polyacrylamide gels.  Following SDS polyacrylamide gel 
electrophoresis (SDS-PAGE), samples were transferred electrophoretically for 
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four amp hours to Hybond-P polyvinylidene difluoride membranes in transfer 
buffer containing 80% methanol and 1g/L SDS.  Membranes were blocked for 
one hour in 1xTBS/0.1%NP40 with 10% newborn calf serum and 5% dry milk. 
 The following primary antibodies were incubated with the appropriate 
membranes: mouse monoclonal anti-MHC antibody (MF20 ref), rabbit polyclonal 
anti-Myf5 antibody (Santa Cruz) diluted 1:1000, and mouse monoclonal anti-actin 
(Sigma) diluted 1:30,000.  Appropriate HRP-conjugated secondary antibodies, 
each diluted 1:1000, were incubated with the membranes for one hour.  After 
each incubation with antibody and prior to the addition of chemiluminescent 
substrate, membranes were washed five times in 1xTBS (tris-buffered saline pH 
7.4) with 1% NP-40.  Membranes were washed a final time with 1x TBS without 
NP-40.  Membranes were then incubated with SuperSignal West Pico 
Chemiluminescent Substrate (Pierce) for 60 seconds and bands were visualized 
using  
Kodak Scientific Imaging Film. 
 
2.4 Cytosolic Nucleosome ELISA 
 
The presence of cytosolic nucleosomes indicative of DNA fragmentation 
and nuclear membrane disruption was used as a marker for apoptosis. 
 Myoblasts were plated at equal density and the next day switched to fresh GM 
or DM.  Cytosolic nucleosomes were measured using the Cell Death Detection 
ELISA Plus Kit (Roche Diagnostics) per manufacturer’s instructions. Briefly, 
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attached cells were rinsed in PBS and then lysed by incubation in 500µL cell lysis 
buffer from the kit on a rocker for 30 minutes at room temperature. Twenty 
microliters of each sample was transferred to a 96-well, flat-bottomed, 
streptavidin-coated microtiter plate.  Seventy-two microliters of 1x incubation 
buffer from the kit, and 4µL each of biotin conjugated anti-histone antibody and 
peroxidase conjugated anti-DNA antibody was added to the lysate in the 
microtiter plate and incubated at 4oC overnight.  Following three washes with 
300µL of incubation buffer, the presence of cytosolic nucleosomes was 
measured by adding 100µL of the substrate, ABTS.  Absorbance at 405nm was 
measured at 60 second intervals using a spectrophotometer.  Values were taken 
from the time point where all samples were within the linear range of the assay 
for each individual experiment. 
 
2.5 Reverse Transcripts And Realtime PCR 
 
Myf5 cDNA was transcribed using SuperScript III (Invitrogen) used per the 
manufacturer’s instructions. The primer sequences used were FMyf5 
(GAAGGTCAACCAGGCTTTCG) and RMyf5 (GTACTGCTCTTTCTGGACC), 
yielding a 252bp fragment.  One other primer pair was used, giving similar 
results.  Sample products were normalized to GAPDH as an internal standard. –
RTs were used as a control for the presence of genomic DNA. 
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CHAPTER III 
RESULTS 
 
3.1 Myf5 Is Capable Of Inducing Differentiation, But Not Apoptosis, When 
Ectopically Expressed 
 
We first compared the level of ectopic Myf5 expression in 10T½ fibroblasts 
to the endogenous levels in C2C12 skeletal myoblasts.  Following transient 
transfection with various amounts of pcMyf5 and Western analysis for Myf5, we 
documented that 10T½ fibroblasts expressed Myf5 protein in a dose-dependent 
fashion (Fig 1).  Transfection with 250ng per 105 cells yielded expression of Myf5 
most comparable to the endogenous Myf5 levels seen in C2C12 myoblasts. 
 
To confirm the functionality of Myf5 in our cells, we sought to recapitulate 
the capability of ectopic expression of Myf5 to induce differentiation in fibroblasts 
which had been reported by others.  Following transient transfection with pcMyf5, 
10T½ fibroblasts were assayed for Myf5 expression via Western analysis (Fig 
2A). Parallel cultures were then switched from growth media  
 13 
 
FIGURE 1. Ectopic Myf5 Expression In 10T½ Fibroblasts.  Equal 
numbers of cells were plated and then transiently transfected with 
either pcDNA or pcMyf5 the next day. Following 24 h of culture in GM, 
lysates were made from the transfected cells.  Western analysis to 
detect Myf5, with actin functioning as a loading and transfer control, 
was performed. 
 
C2C12 23A2 
1000ng 500ng  250ng pcDNA 
     Myf5 
 
      10T½ 
pcMyf5 
    β-actin 
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FIGURE 2. Ectopic Myf5 Expression Is Sufficient To Induce 
Differentiation In Fibroblasts.  In (A), equal cell numbers were plated and 
then transiently transfected with either pcDNA or pcMyf5 the next day. 
Following 24 h of culture in GM, lysates were made from the transfected 
fibroblasts.  Western analysis to detect Myf5, with actin functioning as a 
loading and transfer control, was performed..  In (B), parallel cultures from 
(A) were switched to DM for 48 h and lysates were made.  Western analysis 
to detect MHC, with actin functioning as a loading and transfer control, was 
performed.  For each shown are results for one experiment that are 
representative of three independent experiments. 
  A   B 
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(GM, which contains 10-15% serum) to differentiation media (DM, which contains 
<1% serum) for 48 hours.  Western analysis for Myosin Heavy Chain (MHC), a 
biochemical marker for differentiation, was then performed (Fig 2B).  MHC 
expression was detected in a dose-dependent fashion.  At  Myf5 expression 
levels comparable to the endogenous level detected in the C2C12 myoblasts 
(125ng pcMyf5 per 105 cells), MHC was detectable, confirming the ability of Myf5 
to induce differentiation in fibroblasts. 
 
The ectopic expression of MyoD has been shown by our laboratory and 
others to be capable of inducing differentiation in 10T ½ fibroblasts (Tapscott et 
al. 1988).    In addition, our laboratory has discovered that MyoD expression is 
sufficient to induce apoptosis in fibroblasts when cultured in DM.  Since Myf5’s 
role in inducing differentiation seems to parallel that of MyoD, this raised the 
interesting question of whether its capability to induce apoptosis also follows. 
 
To test this hypothesis, we transiently transfected 10T ½ fibroblasts with 
varying doses of pcMyf5 and assayed for ectopic Myf5 expression via Western 
analysis after overnight culture in GM (Fig 3A).  Following this, parallel cultures 
were then switched to DM for six hours and apoptosis was quantified using the 
Cell Death Detection ELISA Plus Kit (Roche Applied Science), which uses a 
colorimetric assay to measure the concentration of cytosolic nucleosomes in a 
sample (Fig 3B).  23A2 skeletal myoblasts were included as a positive control 
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and the assay is plotted as fold increase from GM to DM.  With increasing doses 
of pcMyf5, up to six times the dose which was comparable 
 17 
 
 
  
FIGURE 3. Ectopic Myf5 Expression Does Not Induce Apoptosis In 
Fibroblasts.  In (A), equal cell numbers were plated and then 
transiently transfected with either pcDNA or pcMyf5 the next day. 
Following 24 h of culture in GM, lysates were made from the 
transfected fibroblasts.  Western analysis for Myf5, with actin 
functioning as a loading and transfer control, was performed.  In (B), 
parallel cultures from (A) were switched to DM for 6 h prior to the 
assessment of DNA fragmentation .  DNA fragmentation was measured 
using the Cell Death Detection ELISA Plus Kit (Roche Applied 
Sciences) as described in Materials and Methods.   For each shown are 
results for one experiment that are representative of three independent 
experiments. Standard error of the mean is given above each data 
point. 
     23A2  
Myf5 
 β-actin 
A 
pcDNA   250ng  500ng    1ug 
   pcMyf5 pcMyf5 pcMyf5                          
B 
    10T½ 
pcDNA  
  10T½ 
  250ng  
  10T½ 
  500ng  
  10T½ 
 1000ng 
  pcMyf5 
 .03 
 .21  <.01  <.01 
 <.01 
 18 
 to endogenous levels of Myf5 in C2C12 myoblasts, we observed a modest to 
negligible increase in cytosolic nucleosomes (especially when compared to the 
35-fold increase in the 23A2 myoblasts).  These data indicate that ectopic Myf5, 
even when overexpressed, is insufficient to induce apoptosis in 10T½ fibroblasts.  
We then speculated that Myf5 might require an unknown protein, expressed in 
myoblasts but not fibroblasts, to induce apoptosis. 
 
Our laboratory used RNAi to knock down MyoD levels in 23A2 skeletal 
myoblasts, creating A2:shMyoD cells. These A2:shMyoD cells were assayed for 
MyoD expression via Western analysis and cultured in DM for sufficient time to 
test for cytosolic nucleosomes (ELISA) or MHC, markers of apoptosis and 
differentiation, respectively.  It was discovered that these MyoD silenced cells are 
defective for both differentiation and apoptosis (Terri Harford, personal 
observation).  Recalling that 23A2 myoblasts do not express detectable levels of 
Myf5 mRNA, we sought to find out whether ectopic Myf5 expression in these 
A2:shMyoD knockdowns would be sufficient to allow for differentiation and/or 
apoptosis.  A2:shMyoD skeletal myoblasts were transiently transfected with 
either pcDNA3, 1ug pcMyf5 per 105 cells, or 2ug pcMyf5 per 105 cells.  Following 
this, we detected Myf5 levels in GM via Western analysis (Fig. 4A) and quantified 
apoptosis in parallel cultures using the Cell Death Detection ELISA Plus Kit 
(Roche Applied Science) (Fig. 4B) following six hours of culture in DM.  
Increasing doses of Myf5 lead to a negligible increase in cytosolic nucleosomes.  
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 pcMyf5 
FIGURE 4. Ectopic Myf5 Expression Does Not Induce Apoptosis In 
A2:shMyoD Myoblasts.  In (A), equal cell numbers were plated and then 
transiently transfected with either pcDNA or pcMyf5 the next day. 
Following 24 h of culture in GM, lysates were made from the transfected 
myoblasts.  Western analysis for Myf5, with actin functioning as a loading 
and transfer control, was performed.  In (B), parallel cultures from (A) 
were switched to DM for 7 h prior to the assessment of DNA 
fragmentation .  DNA fragmentation was measured using the Cell Death 
Detection ELISA Plus Kit (Roche Applied Sciences) as described in 
Materials and Methods. For each shown are results for one experiment 
that are representative of two independent experiments. Standard error 
of the mean is given above each data point. 
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These data indicate that ectopic Myf5 expression was insufficient to restore 
apoptosis in both 10T½ fibroblasts and A2:shMyoD skeletal myoblasts. 
 
 
3.2 Oncogenic Ras Inhibits the Expression Of Myf5 In Both Fibroblasts And 
Myoblasts. 
 
Others have reported that MyoD expression is inhibited in skeletal 
myoblasts expressing oncogenic Ras.  In order to determine whether oncogenic 
Ras also inhibits Myf5 expression, we planned to compare expression levels of 
ectopic Myf5 in 10T½ fibroblasts with expression levels of ectopic Myf5 in 10T½ 
fibroblasts expressing G12V H-Ras expressing fibroblasts. We also planned to 
perform a similar analysis in 23A2 and A2:G12V H-Ras myoblasts. However, we 
first needed to compare the transfection efficiency of these cell lines.  To 
accomplish this, we compared expression of ectopically expressed β-
galactosidase in transiently transfected 10T½ fibroblasts, 10T½:G12V H-Ras 
fibroblasts, 23A2 myoblasts, and A2:G12V H-Ras myoblasts (Fig. 5).  We found 
similar levels of β-gal expression in the three cell lines tested. Next, we 
transiently transfected 10T½ and 10T½:G12V H-Ras fibroblasts with pcMyf5.  
After overnight culture in GM, we performed Western analysis to assess Myf5 
levels in both cells lines and observed a reduction in expression in the 
10T½:G12V H-Ras fibroblasts relative to the 10T½ fibroblasts (Fig 6). 
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     We then tested for Myf5 expression by Western analysis after transiently 
transfecting 23A2 skeletal myoblasts and A2:G12V H-Ras myoblasts with 
increasing doses of pcMyf5 (Fig 7).  A noticeable reduction in Myf5 expression 
occurred in the A2:G12V myoblasts relative to the 23A2 myoblasts. These data, 
when taken together, demonstrate that Myf5 expression is inhibited by the 
presence of oncogenic Ras in both skeletal myoblast and fibroblast lineages. 
 22 
 
FIGURE 5. Transfection Efficiency In Four Fibroblast and Myoblast Cell 
Lines.  Equal cell numbers were plated and then transiently transfected with 
B-gal the next day.  After 24 hours of culture in GM, Cells were fixed and 
stained overnight with X-gal solution.  The proportion of stained cells  to total 
cells in a field of view was calculated and plotted as a percentage.  Error bars 
represent the standard deviation of the mean from three independendent 
simultaneous experiments. 
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FIGURE 6. Ectopic Myf5 Expression Is Inhibited In 10T½:G12V H-Ras 
Fibroblasts. In (A), equal numbers of cells were plated and then transiently 
transfected with either pcDNA or pcMyf5 the next day. Following 24 h of culture 
in GM, lysates were made from the transfected fibroblasts.  Western analysis for 
Myf5, with actin functioning as a loading and transfer control, was performed. 
For each shown are results for one experiment that are representative of three 
independent experiments. In  (B), densitometry analysis was used to quantitate 
protein levels, normalizing to b-actin expression.  
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FIGURE 7. Ectopic Myf5 Expression Is Inhibited In A2:G12V H-
Ras Myoblasts. In (A), equal numbers of cells were plated and then 
transiently transfected with either pcDNA or pcMyf5 the next day. 
Following 24 h of culture in GM, lysates were made from the 
transfected myoblasts.  Western analysis for Myf5, with actin 
functioning as a loading and transfer control, was performed. For 
each shown are results for one experiment that are representative of 
two independent experiments. In (B), densitometry analysis was used 
to quantitate protein levels, normalizing to b-actin expression. 
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3.3 Assessment Of the Mechanism Of Oncogenic Ras Inhibition Of Ectopic 
Myf5 Expression 
 
To uncover the mechanism of the inhibition of ectopic Myf5 expression by 
oncogenic Ras, we first sought to assess the levels of Myf5 mRNA.  All four cell 
lines were transfected with equal amounts of pcMyf5 or pcDNA3. After overnight 
culture in GM, RNA was isolated from lysates and reverse-transcribed to cDNA. 
Myf5 levels were then detected by Realtime PCR.  Similar levels of Myf5 mRNA 
were observed in each of the four cell lines (Fig 8). 
 
We next assayed the effect of oncogenic Ras on the half-life of Myf5 
protein. We transiently transfected 23A2 myoblasts and 23A2:G12V H-Ras 
myoblasts with 250ng pcMyf5 per 105 cells. Following overnight culture in GM, 
the plates of transfected 23A2 cells were pooled and the plates of transfected 
23A2:G12V cells were pooled to control for transfection efficiency. These cells 
were then replated at 4x105 cells per 100mm culture dish. Following overnight 
culture, cycloheximide was added to the plates to halt global translation. Lysates 
were made at various timepoints and assayed for Myf5 expression by Western 
Analysis (Fig 9) and the halflife of Myf5 was assessed by densitometry analysis. 
The presence of oncogenic Ras did not reduce the half-life of Myf5 protein. 
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Concurrently, the same experiment was performed in two fibroblast 
lineages, 10T½ and 10T½:G12V H-Ras (Fig 10).  In this case, again, the 
presence of oncogenic Ras did not reduce the half-life of Myf5 protein. 
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FIGURE 8. Oncogenic Ras Does Not Affect the mRNA Levels Of Ectopic 
Myf5. Equal   numbers of cells were plated and then transiently transfected with 
250ng pcMyf5 the next day. Following 24 h of culture in GM cells were lysed 
and RNA extraction was performed.  Myf5 cDNA was transcribed by reverse 
transcription via SuperScript III (Invitrogen). Quantitative realtime PCR was 
performed and subsequent C(t) analysis is shown. 
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FIGURE 9. Oncogenic Ras Does Not Reduce the Half-life Of 
Myf5 Protein In Skeletal Myoblasts. Equal numbers of cells were 
plated and then transiently transfected with pcMyf5 the next day. 
Following 24 h of culture in GM, cells were pooled and replated at 
4x105.  Following overnight culture in GM, cells were treated with a 
timecourse of cycloheximide for 0, 30, 60, 120, or 180 minutes. 
Lysates were made. Western analysis for Myf5, with actin 
functioning as a loading and transfer control, was performed. 
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FIGURE 10. Oncogenic Ras Does Not Reduce the Half-life Of Myf5 
Protein In Fibroblasts. Equal numbers of cells were plated and then 
transiently transfected with pcMyf5 the next day. Following 24 h of culture 
in GM, cells were pooled and replated at 4x105.  Following overnight 
culture in GM, cells were treated with a timecourse of cycloheximide for 
0, 30, 60, 120, or 180 minutes. Lysates were made. Western analysis for 
Myf5, with actin functioning as a loading and transfer control, was 
performed. Densitometry analysis was performed to determine protein 
half-life. Sample bands were normalized to actin. 
    β-actin 
 
 
     Myf5 
 
  0       30      60     120   180         Time (min) 
 30 
 
 
 
 
 
CHAPTER IV 
DISCUSSION 
 
 
4.1 Myf5 Plays a Role In Skeletal Myoblast Differentiation But Not the 
Coordinated Apoptosis.  
 
While differentiation and apoptosis are well-established as critical 
processes for vertebrate development, knowledge of the coordinate regulation of 
these processes at the molecular level is not well understood.  Skeletal 
myogenesis has long served as the paradigm in which to study the molecular 
regulation of differentiation since it is easily recapitulated using cell culture 
models.  Culture in media lacking serum (differentiation media: DM) mimics the 
decreasing gradient of growth factors required in vivo to allow the degredation of 
Id, thus allowing MyoD and Myf5 to function.  Using these cell culture models, 
our lab and others have reported that when cultured in DM, 30 percent of 
myoblasts undergo apoptosis rather than differentiation (Walsh 1997; Wang et al. 
1997).  Further, expression of oncogenic Ras blocks both differentiation and 
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apoptosis (Weyman 1997). Thus, differentiation and apoptosis are each induced 
by culture in DM, while each is inhibited by expression of oncogenic Ras.  10T½ 
fibroblasts quiesce when cultured in DM (Boraldi et al. 2008).   
 
Both the MyoD and Myf5 transcription factors are capable of converting 
multipotential 10T½ fibroblasts into determined myoblasts that express muscle-
specific genes when cultured in DM.  Further, expression of MyoD in 10T ½ 
fibroblasts has recently been shown to be sufficient to allow for apoptosis in 
response to culture in DM (Terri Harford). 
 
However, data presented herein has shown that expression of Myf5 is not 
sufficient to allow for apoptosis in 10T½ fibroblasts cultured in DM.  Further, in 
23A2 skeletal myoblasts that do not express endogenous Myf5 and that are 
silenced for MyoD expression as a consequence of RNAi, we have shown that 
ectopic expression of Myf5 cannot compensate for the ability of MyoD to allow for 
apoptosis. 
 
Our findings are consistent with the work of others.  Recently, these MyoD 
null myoblasts were shown to have increased survival following transplantation 
suggesting an impaired apoptotic phenotype.  Myoblasts derived from MyoD null 
mice have a fivefold elevation in the expression of Myf5, yet display an impaired 
differentiation phenotype (Smythe and Grounds 2001).  These results support a 
role for MyoD, but not Myf5, in both the differentiation and apoptotic processes 
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during regeneration.  Finally, it is broadly accepted that Myf5 compensates for 
the absence of MyoD during developmental differentiation.  However, if apoptosis 
is to play a key role during developmental myogenesis, we must speculate that a 
molecule other than MyoD can contribute to the apoptotic process since MyoD 
null mice are developmentally normal. 
 
4.2 Myf5 Expression Is Regulated By Oncogenic Ras 
 
          Cancer is considered a disease of defective differentiation and defective 
apoptosis.   Perhaps it should have been expected, then, that proteins capable of 
inducing cancer would regulate molecules responsible for inducing differentiation 
and/or apoptosis.  Abrogation of MyoD expression by oncogenic Ras in skeletal 
myoblasts was reported almost 20 years ago (Olson et al. 1987). However, the 
mechanism for this inhibition has not yet been discovered. Likewise, here we 
have shown that the expression of oncogenic Ras is sufficient to diminish 
expression of Myf5 in fibroblasts and myoblasts.  This leaves open the possibility 
that signaling through oncogenic Ras is affecting both MyoD and Myf5 through a 
common mechanism. 
 
 There are several different mechanisms by which oncogenic Ras could be 
affecting the expression of Myf5.  One such model can be eliminated 
immediately. As the Myf5 expression we are dealing with is ectopic, it is driven by 
the strong CMV promoter located on the vector and should therefore overcome 
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any transcriptional inhibition present.  This is not to say that oncogenic H-Ras 
does not downregulate the endogenous transcription of the Myf5 gene.  
However, testing this hypothesis would require stable expression of H-Ras in a 
myoblast cell line which endogenously expressed Myf5 such as C2C12.   
 
 Oncogenic Ras could result in a decreased half-life of Myf5 mRNA.  Our 
results showing equal levels of Myf5 mRNA regardless of the expression of 
oncogenic Ras indicate that this is not the case.  However, rigorous proof would 
require the use of Northern hybridization to determine whether or not Ras affects 
Myf5’s messenger RNA half-life.  Once again, it is worth noting that this is the 
half-life of ectopic Myf5, and studying oncogenic Ras’s effects on endogenous 
Myf5 would require a myoblast cell line which stably expresses it. 
 
 Oncogenic Ras could be downregulating the expression of Myf5 by 
affecting its protein stability.  Our results show that in two different sets of 
experiments this does not appear to be the case (Figs. 9-10).  In both fibroblasts 
and myoblasts, the protein half-life of Myf5 is not reduced; in point of fact, it is 
very slightly increased.   
 
 Finally, oncogenic Ras could affect the translation of Myf5.  This could be 
effectively tested through S35-methionine metabolic labeling followed by 
immunoprecipitation and quantitative comparison of the labeled Myf5 from 
parentals and cells expressing oncogenic Ras.  Elucidating the precise 
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mechanism whereby oncogenic Ras prevents the expression of MyoD and/or 
Myf5 might identify anti-cancer therapeutic targets. 
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